The purpose of this study is to explore the efficacy and safety ofof bevacizumab plus cisplatin compare with cisplatin in the treatment of malignant serous effusion in patients with advanced adenocarcinoma
Voluntarily sign informed consent;
Treatment naive serous effusion of patients with adenocarcinoma without activating gene mutation.
Eastern Cooperative Oncology Group (ECOG) score ≤ 2;
Survival is expected to exceed 3 months
The subject had received anti-vascular endothelial growth factor (VEGF) small molecule tyrosine kinase inhibitors or monoclonal antibodies in the past 4 weeks; The subject had participated any clinical trials in the past 4 weeks; The subject had previously received bevacizumab of pleural perfusion therapy;